180 Life Sciences Corp.
ATNF
$1.04
-$0.01-0.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.03% | 69.06% | 92.28% | 75.71% | 63.95% |
| Total Depreciation and Amortization | -67.66% | -44.80% | -30.24% | 7.29% | 3.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -62.58% | -67.53% | -97.62% | -77.78% | -69.95% |
| Change in Net Operating Assets | 579.22% | 12,387.94% | -107.32% | -89.52% | -127.10% |
| Cash from Operations | 83.91% | 86.44% | 76.99% | 68.60% | 41.93% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -8.63% | -8.63% | -8.63% |
| Total Debt Repaid | -1.85% | -6.06% | -9.67% | 23.77% | 35.30% |
| Issuance of Common Stock | -21.38% | -21.37% | -93.07% | -75.28% | -45.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 94.36% | 72.60% | 37.46% |
| Cash from Financing | -29.68% | -31.66% | -95.73% | -75.60% | -44.01% |
| Foreign Exchange rate Adjustments | 2,200.00% | 161.00% | -232.46% | -139.08% | 112.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 254.73% | 152.25% | -166.45% | -324.91% | 34.82% |